Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form 4

NovaBay Pharmaceuticals, Inc. Form 4 January 04, 2017

January 04,	2017											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION										OMB APPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION								N OMB Number:	3235-0	287		
Check the check	MENT OF (Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF					Expires:		31, 005			
Subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 									0.5			
(Print or Type	Responses)											
1. Name and Freiman Pa		2. Issuer Name and Ticker or Trading Symbol NovaBay Pharmaceuticals, Inc. [NBY]				ing	5. Relationship of Reporting Person(s) to Issuer					
						(Check all applicable)						
		(M 0 C., 5980		of Earliest T Day/Year) 2017	ransaction			X Director Officer (gi below)		% Owner her (specify		
			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line)				
EMERYVI	LLE, CA 94608								y One Reporting I y More than One F			
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Secu	rities A	cquired, Disposed	of, or Beneficia	ally Owned		
1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		ate, if	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	(D)	Price	, , ,				
Reminder: Re	port on a separate line	e for each class	s of secu	urities bene	-		-	or indirectly.	ection of	SEC 1474		

information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion (Month/Day/Year) Execution Date r Exercise any rice of (Month/Day/Year) erivative		 4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
stock option (right to buy) (2)	\$ 3.24	01/03/2017		A	25,916	01/03/2017(1)	01/03/2027	Common Stock	25,910

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting O when Plane / Plane of	Director	10% Owner	Officer	Othe		
Freiman Paul E. C/O NOVABAY PHARMACEUTICALS, INC. 5980 HORTON STREET, SUITE 550 EMERYVILLE, CA 94608	Х					
Signatures						
/s/ Justin Hall as attorney in fact for Paul Freiman	01	/04/2017				
**Signature of Reporting Person		Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Stock options will vest in equal monthly installments over one year starting from the date of grant
- (2) Granted pursuant to the 2007 Omnibus Incentive Plan and the 2017 Non-Employee Director Compensation Plan

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.